Phase 3 Clinical Trials With Primary Completion Dates in June 2017
This is a list of Phase 3 trials with primary completion dates in June 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | 2017-06-01 | Phase 3 | NCT02558400 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
| AMAG | AMAG Pharmaceuticals, Inc. | 2017-06-01 | Phase 3 | NCT02694978 | A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) |
| ARDX | Ardelyx, Inc. | 2017-06-01 | Phase 3 | NCT02621892 | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C |
| AXSM | Axsome Therapeutics, Inc. | 2017-06-01 | Phase 3 | NCT02504008 | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 |
| BIVV | Bioverativ Inc. | 2017-06-01 | Phase 3 | NCT01425723 | Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B |
| CBPO | China Biologic Products, Inc. | 2017-06-01 | Phase 3 | NCT02623556 | Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen |
| CLVS | Clovis Oncology, Inc. | 2017-06-01 | Phase 3 | NCT02322281 | TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy |
| CRMD | CorMedix Inc | 2017-06-01 | Phase 3 | NCT02651428 | Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection |
| EYEG | Eyegate Pharmaceuticals, Inc. | 2017-06-01 | Phase 3 | NCT02517619 | Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis |
| FGEN | FibroGen, Inc | 2017-06-01 | Phase 3 | NCT02278341 | Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis |
| GRFS | Grifols, S.A. | 2017-06-01 | Phase 3 | NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations |
| HZNP | Horizon Pharma plc | 2017-06-01 | Phase 3 | NCT01197378 | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) |
| KTOV | Kitov Pharmaceuticals Holdings Ltd. | 2017-06-01 | Phase 3 | NCT02979197 | Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives |
| MESO | Mesoblast Limited | 2017-06-01 | Phase 3 | NCT02336230 | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD |
| MNK | Mallinckrodt plc | 2017-06-01 | Phase 3 | NCT02282930 | Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression |
| NAVB | Navidea Biopharmaceuticals, Inc. | 2017-06-01 | Phase 3 | NCT01886820 | A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology |
| NBIX | Neurocrine Biosciences, Inc. | 2017-06-01 | Phase 3 | NCT02736955 | Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia |
| NOVN | Novan, Inc. | 2017-06-01 | Phase 3 | NCT02798120 | P3 Long Term Safety Study of Once Daily SB204 in Acne |
| NVIV | InVivo Therapeutics Holdings Corp. | 2017-06-01 | Phase 3 | NCT02138110 | The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury |
| PRAH | PRA Health Sciences, Inc. | 2017-06-01 | Phase 3 | NCT02491437 | A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II) |
| PTCT | PTC Therapeutics, Inc. | 2017-06-01 | Phase 3 | NCT02090959 | Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy |
| RARE | Ultragenyx Pharmaceutical Inc. | 2017-06-01 | Phase 3 | NCT02377921 | Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) |
| RDY | Dr. Reddy's Laboratories Ltd | 2017-06-01 | Phase 3 | NCT02569853 | DFN-11 Injection in Episodic Migraine With or Without Aura |
| SAGE | Sage Therapeutics, Inc. | 2017-06-01 | Phase 3 | NCT02477618 | A Study With SAGE-547 for Super-Refractory Status Epilepticus |
| ZGNX | Zogenix, Inc. | 2017-06-01 | Phase 3 | NCT02826863 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |
| ZGNX | Zogenix, Inc. | 2017-06-01 | Phase 3 | NCT02823145 | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome |